Literature DB >> 9401495

Levels of Hb A2 in heterozygotes and homozygotes for beta-thalassemia mutations: influence of mutations in the CACCC and ATAAA motifs of the beta-globin gene promoter.

T H Huisman1.   

Abstract

The author summarizes the Hb A2 levels in over 600 beta-thalassemia heterozygotes with 32 different base changes or frameshifts and in 22 heterozygotes for 1 of 5 large deletions. Three major groups are recognized: persons with beta zero-thalassemia or beta (+)-thalassemia (severe) have Hb A2 levels between 4.5 and 5.5%, those with mild beta (+)-thalassemia alleles have levels between 3.6 and 4.2%, with still lower values for those with silent mutations. High values were observed in subjects with the 2 mild beta + alleles with mutations in the beta-globin gene promoter (-88, C-->T and -29, A-->G); unusually high Hb A2 values were also present in several -88 and -29 homozygotes. Data for several members of 8 families in which the -88 (C-->T) or the -29 (A-->G) mutation, or the -1,393-bp deletion, is present in cis or in trans to a delta-globin gene mutation support earlier observations that an increase in delta-chain synthesis occurs in cis to either one of these 3 alleles. A review of these data confirms the suggestion that the increase in Hb A2 levels results from at least two mechanisms: in a posttranslational system, the formation of alpha delta-dimers is promoted when excess alpha-chains are available, while certain promoter mutations increase the transcription of the delta-globin gene in cis because of a change in the binding of transcription factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401495     DOI: 10.1159/000203622

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  11 in total

1.  Diagnosis of Beta-thalassaemia carriers in the sultanate of oman.

Authors:  Shahina Daar; David Gravell
Journal:  Sultan Qaboos Univ Med J       Date:  2006-06

Review 2.  Molecular basis of β thalassemia and potential therapeutic targets.

Authors:  Swee Lay Thein
Journal:  Blood Cells Mol Dis       Date:  2017-06-20       Impact factor: 3.039

3.  Disrupting the adult globin promoter alleviates promoter competition and reactivates fetal globin gene expression.

Authors:  Sarah K Topfer; Ruopeng Feng; Peng Huang; Lana C Ly; Gabriella E Martyn; Gerd A Blobel; Mitchell J Weiss; Kate G R Quinlan; Merlin Crossley
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

4.  Fetal-haemoglobin enhancing genotype at BCL11A reduces HbA2 levels in patients with sickle cell anaemia.

Authors:  Titilope A Adeyemo; Oyesola O Ojewunmi; Idayat Ajoke Oyetunji; Olufunto Olufela Kalejaiye; Stephan Menzel
Journal:  EJHaem       Date:  2021-05-04

5.  Sandwich ELISA for hemoglobin A2 quantification and identification of beta-thalassemia carriers.

Authors:  Surakit Kuntaruk; Thanusak Tatu; Tiemjan Keowkarnkah; Watchara Kasinrerk
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

Review 6.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 7.  The molecular basis of β-thalassemia.

Authors:  Swee Lay Thein
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

8.  Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.

Authors:  Yongliang Huo; Sean C McConnell; Thomas M Ryan
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

Review 9.  Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants.

Authors:  Andrew Perkins; Xiangmin Xu; Douglas R Higgs; George P Patrinos; Lionel Arnaud; James J Bieker; Sjaak Philipsen
Journal:  Blood       Date:  2016-02-22       Impact factor: 22.113

10.  Hemoglobin A2 Lowered by Iron Deficiency and α -Thalassemia: Should Screening Recommendation for β -Thalassemia Change?

Authors:  Srdjan Denic; Mukesh M Agarwal; Bayan Al Dabbagh; Awad El Essa; Mohamed Takala; Saad Showqi; Javed Yassin
Journal:  ISRN Hematol       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.